GlassScriptPhysician profile
Brandon Wade Aiman
NPI 1831124999
$10,448.89
in general payments reported to CMS, 2019-2025
34 companies · $2,082 in 2025
The $2,082 reported for 2025 was more than what 91% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,905 · 2022: $2,290 · 2023: $2,048 · 2024: $2,123 · 2025: $2,082.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,175 · Education: $78.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,174.78 |
| Education | $78.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,997.36 | 2021-2025 | Fasenra, Tezspire, Breztri |
| Glaxosmithkline, LLC. | $1,718.03 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Regeneron Healthcare Solutions, INC. | $784.17 | 2021-2025 | Dupixent |
| Genzyme Corporation | $753.94 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $497.29 | 2021-2025 | Glassia |
| Mallinckrodt Hospital Products INC. | $474.62 | 2021-2025 | Acthar |
| Grifols USA, LLC | $460.30 | 2021-2025 | Prolastin-C Liquid, Xembify |
| Actelion Pharmaceuticals US, INC. | $355.07 | 2022-2025 | Uptravi, Opsumit, Opsynvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $354.96 | 2021-2025 | Ofev, Jascayd |
| Janssen Pharmaceuticals, INC | $338.98 | 2021-2023 | Xarelto |
| Mylan Specialty L.P. | $315.58 | 2021-2024 | Yupelri |
| Novartis Pharmaceuticals Corporation | $284.84 | 2021-2025 | |
| United Therapeutics Corporation | $251.97 | 2021-2024 | Tyvaso |
| Amgen INC. | $250.42 | 2022-2025 | Tezspire |
| Pfizer INC. | $180.92 | 2021-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $155.52 | 2021-2023 | |
| Insmed, INC. | $151.07 | 2022-2025 | Arikayce, Brinsupri |
| E.R. Squibb & Sons, L.L.C. | $148.95 | 2021-2024 | Eliquis |
| Axsome Therapeutics, INC. | $143.23 | 2022-2025 | Sunosi |
| Merck Sharp & Dohme LLC | $116.44 | 2021-2024 | Zerbaxa, Dificid, Recarbrio |
| Gilead Sciences, INC. | $107.18 | 2021-2022 | |
| Baxter Healthcare | $100.16 | 2022-2025 | Hillrom - Monarch Airway Clearance System, Hillrom - Life 2000 Ventilation System |
| Verona Pharma, INC. | $97.12 | 2025 | Ohtuvayre |
| Philips North America LLC | $82.54 | 2022-2025 | Vest Therapy Und |
| Genentech USA, INC. | $70.80 | 2021-2025 | Xolair |
| Viatris Specialty LLC | $49.26 | 2025 | Yupelri |
| Eisai INC. | $40.22 | 2021 | |
| Inspire Medical Systems, INC. | $33.02 | 2025 | Inspire |
| Idorsia Pharmaceuticals US INC | $32.13 | 2023 | Quviviq |
| Avadel Cns Pharmaceuticals, LLC | $25.08 | 2024 | Lumryz |
| Harmony Biosciences LLC | $22.98 | 2021 | |
| Ani Pharmaceuticals, INC. | $22.29 | 2025 | Purified Cortrophin Gel |
| Collegium Pharmaceutical, INC. | $16.93 | 2024 | Belbuca |
| Teva Pharmaceuticals USA, INC. | $15.52 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Aiman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.